The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).
Emmanuel S. Antonarakis
Consultant or Advisory Role - Janssen Biotech
Honoraria - Janssen Biotech
Research Funding - Johnson & Johnson
Changxue Lu
No relevant relationships to disclose
Hao Wang
No relevant relationships to disclose
Brandon Luber
No relevant relationships to disclose
Mary Nakazawa
No relevant relationships to disclose
Yan Chen
No relevant relationships to disclose
Jeffrey C. Roeser
No relevant relationships to disclose
Helen L. Fedor
No relevant relationships to disclose
Tamara L. Lotan
No relevant relationships to disclose
Qizhi Zheng
No relevant relationships to disclose
Angelo M. De Marzo
No relevant relationships to disclose
John T. Isaacs
No relevant relationships to disclose
William B. Isaacs
No relevant relationships to disclose
Rosa Nadal
No relevant relationships to disclose
Channing Judith Paller
No relevant relationships to disclose
Samuel R. Denmeade
No relevant relationships to disclose
Michael Anthony Carducci
No relevant relationships to disclose
Mario A. Eisenberger
No relevant relationships to disclose
Jun Luo
No relevant relationships to disclose